Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats.

Virology - 20 Jan 2004

Zhao Xiaodong, Chen Fu-Ping, Sullender Wayne M

Abstract excerpt

Palivizumab (PZ) is the only monoclonal antibody in human use against an infectious disease. PZ is a humanized monoclonal antibody that recognizes the fusion protein of respiratory syncytial virus (RSV). PZ prophylaxis reduces the likelihood of hospitalization for young children at risk for severe RSV infections. The quasispecies nature of RNA viruses allows rapid emergence of viruses with a selective advantage....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiviral Agents

Share to Disease Models, Animal

Share to Respiratory Syncytial Virus Infections

Share to Respiratory Syncytial Viruses

Share to Sigmodontinae

Source

Identifiers

PMID: 14972528
DOI: 10.1016/j.virol.2003.10.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats.PMID 14972528Read ↗

In Vivo Selection of Respiratory Syncytial Viruses Resistant to PalivizumabSemantic proximity Read ↗

Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants.Semantic proximity Read ↗

In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants.Semantic proximity Read ↗

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.Semantic proximity Read ↗

Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.Semantic proximity Read ↗

Evaluation of a non-nucleoside inhibitor of the RSV RNA-dependent RNA polymerase in translatable animals modelsSemantic proximity Read ↗

A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton RatsSemantic proximity Read ↗

Mathematical Modeling Identifies the Role of Adaptive Immunity as a Key Controller of Respiratory Syncytial Virus (RSV) Titer in Cotton RatsSemantic proximity Read ↗

Mathematical Modeling Identifies the Role of Adaptive Immunity as a Key Controller of Respiratory Syncytial Virus (RSV) Titer in Cotton RatsSemantic proximity Read ↗

Palivizumab‐Resistant Human Respiratory Syncytial Virus Infection in InfancySemantic proximity Read ↗

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.Semantic proximity Read ↗

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.